African Export-Import Bank (Afreximbank) has committed $2b facility to the “Africa Health Security Investment Plan” to support the health product manufacturing ambition of the continent.
The commitment was made under a renewed partnership between Afreximbank and the Africa Centers for Diseases Control and Prevention (Africa CDC) on Thursday.
A statement issued by Vincent Musumba, Manager, Communications and Events, Afreximbank, said the cooperation agreement was announced on the sidelines of the Global Forum for Vaccine Sovereignty and Innovation in Paris, France.
Read also: First Bank secures $200m facility from Afreximbank for manufacturing customers, others
Musumba said the initiative would focus on the African Pooled Procurement Mechanism (APPM) and the Platform for Harmonised African Health Products Manufacturing (PHAHM).
He said the initiative was pivotal in addressing Africa’s health investment challenges, promoting economic development, and strengthening health security across the continent.
“ It also intends to complement GAVI’s innovative financing mechanism, the African Vaccine Manufacturing Accelerator (AVMA).Which is set to provide up to two billion dollars in financing to African manufacturers of health and pharmaceutical products over the next 10 years.”
He said African pharmaceutical companies faced severe impacts of global health, security and economic challenges, yet they were the drivers of investments and technology advancements that the health sector needs.
“Low investor confidence, lack of appropriate infrastructure, trade-related barriers, and regulatory challenges are some of the constraints to investment in Africa’s health sector.
Read also: Nigeria’s manufacturing growth slows to 1.49% in first quarter
“While funds might be available, many potential investments do not materialise due to financial and non-financial obstacles.Coordinated efforts at the continental level are essential to reverse this trend and align with the New Public Health Order.”
He said closing the investment gap would be crucial to achieving the African Union’s ambition of manufacturing 60 per cent of vaccines needed locally by the year 2040.
